TMED9 and central nervous system cancer: Our analysis of TMED9 expression in primary and recurrent glioma tumors demonstrated a significant increase in TMED9 in recurrent LGG tumors (Figure 1E) with no significant difference in recurrent GBM tumors (Figure 1F).